Skip to main content

Table 1 Change in tumor volume before and after treatment

From: The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

Group Volume Week 1 (mm3) Volume Week 12 (mm3) Volume change (mm3)
Control 65 ± 15.3 1447.7 ± 291.3 1382.7 ± 276
Bz alone 104 ± 6.6 1049.4 ± 381 945.4 ± 374.4
Bz → HB 104 ± 9.7 702.3 ± 260.3 598.3 ± 250.5
HB → Bz 64.6 ± 7.5 538.5 ± 281.5 473.9 ± 274.1
  1. Mean tumor volumes ± SEM are listed for each group at weeks 1 and 12 of the study. Change in tumor volume between week 1 and week 12 are listed in the final column. The arrow denotes the order of treatment. Bz = Bortezomib, HB = HB 22.7. n = 5 mice per group